A New Frontier for GLP-1 Therapies 

Few therapeutic classes have generated as much attention as GLP-1 therapies in recent years. Initially developed for glycemic control in Type 2 diabetes, they have since been studied and used across obesity, weight management, and cardiovascular-related indications, and a new chapter in their clinical application is now emerging. 

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, researchers presented observational data exploring the association between GLP-1 therapy use and metastatic progression (the spread of cancer from its original site to other parts of the body) in several cancer types. 

These findings have generated discussion across multiple stakeholder groups, including researchers and clinicians.  

What ASCO 2026 Is Telling Us 

Among the most discussed studies was a large real-life analysis of more than 12,000 patients across seven obesity-related cancers. Researchers observed lower rates of progression to Stage IV disease among patients receiving GLP-1 receptor agonists compared to a control group receiving DPP-4 inhibitors (an alternative Type 2 diabetes treatment). 

Particularly statistically significant findings were observed in: 

• Breast cancer 

• Non-small cell lung cancer (NSCLC) 

• Colorectal cancer (CRC) 

• Liver cancer (specifically HCC) 

The use of GLP-1 therapies was associated with 38% to 50% lower likelihood of progression to stage IV disease compared with the control group.  

Additional research explored: 

• Reduced incidence of some obesity-related cancers 

• Improved survival outcomes in certain cohorts 

• Potential interactions with immune checkpoint inhibitor therapies that warrant further investigation 

• Underlying biological mechanisms involving inflammation and tumor microenvironments 

While further research is needed, these findings contribute to ongoing research into the relationship between metabolic health and cancer-related measures. 

Areas for Future Research 

If future research supports these observations, it may help inform future scientific understanding in this area. 

Potential impacts include: 

• New preventative oncology approaches 

• Exploration of links between obesity management and oncology care 

• Additional research into potential therapeutic applications 

• Research into survivorship-related considerations 

• Better understanding of risk-related factors 

For healthcare systems facing rising obesity-related cancer burdens, these findings may have potential implications for future research into cancer prevention and treatment. 

The Questions We Still Need to Answer 

The data appears promising, but caution remains essential. 

Key questions include: 

• Are these findings causal or associative? 

• Which Patients benefit most? 

• What role does weight loss play versus direct biological effects? 

• Are outcomes consistent across tumor types? 

• How should GLP-1 therapies be integrated into existing oncology pathways? 

These questions are likely to drive research agendas long after ASCO 2026 concludes. 

Conclusion 

ASCO 2026 has contributed new data to ongoing discussions about the future research potential of GLP-1 therapies. 

Researchers continue to explore whether GLP-1 therapies may have relevance beyond their currently established areas of use. The findings are of scientistic interest and warrant further investigation. But the most important developments may still lie ahead as researchers continue to investigate potential relationships between metabolic health and cancer-related outcomes. 

Disclaimer: The research discussed in this article is based on observational data presented at ASCO 2026. The findings are preliminary, do not establish causality, and should not be interpreted as evidence of clinical benefit, treatment recommendations, or future regulatory approvals. 

References 

• ASCO – Annual Meeting 
• GLP May Reduce Metastatic Progression
• GLP-1 Agonists Associate with Major Reduction in Metastatic Cancer Progression 
• GLP-1 Receptor Agonists Show Promise in ASCO 2026 Research 
• ASCO 2026 – GLP-1s Could Reduce the Risk of Some Obesity Related Cancers Progressing
• Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.